KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Retained Earnings (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Retained Earnings for 8 consecutive years, with -$2.1 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 99.73% to -$2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.1 million through Dec 2025, up 99.73% year-over-year, with the annual reading at -$2.1 million for FY2025, 99.73% up from the prior year.
  • Retained Earnings hit -$2.1 million in Q4 2025 for Vir Biotechnology, up from -$1.2 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $774.3 million in Q2 2021 to a low of -$1.2 billion in Q3 2025.
  • Historically, Retained Earnings has averaged -$213.5 million across 5 years, with a median of -$3.1 million in 2023.
  • Biggest five-year swings in Retained Earnings: skyrocketed 262574.58% in 2021 and later plummeted 36643.8% in 2025.
  • Year by year, Retained Earnings stood at -$1.1 million in 2021, then plummeted by 730.03% to -$9.1 million in 2022, then plummeted by 2507.15% to -$237.8 million in 2023, then plummeted by 219.47% to -$759.8 million in 2024, then surged by 99.73% to -$2.1 million in 2025.
  • Business Quant data shows Retained Earnings for VIR at -$2.1 million in Q4 2025, -$1.2 billion in Q3 2025, and -$991.7 million in Q2 2025.